Tislelizumab plus sitravatinib or anlotinib as maintenance therapy in extensive‐stage small‐cell lung cancer: Results of two prospective phase II studies
- 6 November 2025
- journal article
- Published by Wiley in International Journal of Cancer
- Vol. 158 (7) , 1916-1926
Abstract
First‐line chemo‐immunotherapy has significantly improved survival in extensive‐stage small‐cell lung cancer (ES‐SCLC). However, rapid disease progression still occurs, with a median progression‐free survival (PFS) of only 4.5–5.8 months from induction therapy. We initiated two single‐arm, phase II studies to assess the first‐line maintenance therapy with tislelizumab plus anti‐angiogenic drugs following induction therapy in ES‐SCLC patients. Previously untreated ES‐SCLC patients were enrolled to receive tislelizumab plus platinum‐based chemotherapy as induction therapy for 4 cycles, followed by tislelizumab plus sitravatinib (Trial 1) or anlotinib (Trial 2) as maintenance therapy in a 21‐day cycle. The primary endpoint was the 1‐year PFS rate in the maintenance analysis set (MAS, including patients receiving ≥1 dose of maintenance therapy). Outcomes in MAS were calculated from the start of maintenance therapy. Twenty‐one patients were enrolled, and 18 patients entered the maintenance phase in each trial. From the start of the maintenance therapy, the median PFS was 6.4 and 7.8 months (1‐year PFS rates of 22.2% and not reached), respectively; the median overall survival (OS) was 18.3 months and not reached. From induction therapy, the corresponding median PFS was 9.1 and 10.8 months, with a median OS of 17.6 months and not reached. In MAS, the most common grade ≥3 treatment‐related adverse events (TRAEs) included hypertension (22.2%) in Trial 1 and fatigue (5.6%) in Trial 2. No patients died from TRAEs in either trial. Maintenance therapy with tislelizumab plus sitravatinib or anlotinib yielded clinically meaningful survival results and was generally well tolerated in ES‐SCLC, warranting further exploration in larger‐scale trials.Keywords
Funding Information
- BeiGene
This publication has 27 references indexed in Scilit:
- Sintilimab plus anlotinib as second or further-line therapy for extensive disease small cell lung cancer: a phase 2 investigator-initiated non-randomized controlled trialeClinicalMedicine, 2024
- LBA93 EXTENTORCH: A randomized, phase III trial of toripalimab versus placebo, in combination with chemotherapy as a first-line therapy for patients with extensive stage small cell lung cancer (ES-SCLC)Annals of Oncology, 2023
- LBA9 Updated results of first-line serplulimab versus placebo combined with chemotherapy in extensive-stage small cell lung cancer: An international multicentre phase III study (ASTRUM-005)Annals of Oncology, 2022
- Effect of First-Line Serplulimab vs Placebo Added to Chemotherapy on Survival in Patients With Extensive-Stage Small Cell Lung CancerJAMA, 2022
- First-in-human phase 1/1b study to evaluate sitravatinib in patients with advanced solid tumorsInvestigational New Drugs, 2022
- Brief Report: Exploratory Analysis of Maintenance Therapy in Patients With Extensive-Stage SCLC Treated First Line With Atezolizumab Plus Carboplatin and EtoposideJournal of Thoracic Oncology, 2022
- IMpower150 Final Overall Survival Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in First-Line Metastatic Nonsquamous NSCLCJournal of Thoracic Oncology, 2021
- Camrelizumab Plus Apatinib in Extensive-Stage SCLC (PASSION): A Multicenter, Two-Stage, Phase 2 TrialJournal of Thoracic Oncology, 2021
- Safety and patient-reported outcomes of atezolizumab, carboplatin, and etoposide in extensive-stage small-cell lung cancer (IMpower133): a randomized phase I/III trialAnnals of Oncology, 2020
- Antiangiogenesis Strategies Revisited: From Starving Tumors to Alleviating HypoxiaCancer Cell, 2014